RecruitingRecurrent Acute Pancreatitis
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
Eligible age
18–85 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.
Sponsor: University of Alabama at Birmingham
Where it's recruiting
Source: ClinicalTrials.gov · NCT06253117 · last updated 2026-07-29